source
- FDA approves Roivant's oral dermatomyositis drug Lisraya (brepocitinib)The U.S. Food and Drug Administration has granted approval to Roivant's drug brepocitinib, which will be sold under the brand name Lisraya. The decision marks the first major regulatory clearance f…
- Gilead secures another FDA approval for HIV therapy, bolstering lenacapavir portfolioGilead Sciences announced that the U.S. Food and Drug Administration has approved a new HIV treatment, adding to the company's growing portfolio of antiviral drugs. The approval extends the reach o…